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dKey concepts
n The human immune system consists of two connected compartments e the innate and adaptive e which
function via the actions of secreted and cellular effectors
n The innate and adaptive immune systems work sequentially to identify invaders and formulate the most
appropriate response; this interaction is crucially bridged by specialised antigen-presenting cells (APCs)
n The innate response, via the action of APCs, sets the scene for the subsequent adaptive response by providing
information about the nature of the threat
n Primary exposure to a pathogen or antigen induces the production of a population of adaptive immune cells with
antigen speciﬁcity that are retained for long periods and provide a rapid response upon subsequent exposure
n The vaccine concept is based on stimulating the body’s defence mechanisms against a speciﬁc pathogen to
establish this immunological memory
n Current vaccine strategies take advantage of immunological mechanisms, and often target the innate immune
system and APCs to induce the desired speciﬁc adaptive immune response
n Future research is also set to examine ways of making the immune response more effective in generating cross
protective responses against different subtypes or strains of pathogens exhibiting antigenic variation2011 Elsevier B.V.
oi:10.1016/j.pervac.2011.05.002
Open access under CC BY-NC-ND license.
26 UNDERSTANDING MODERN VACCINESImmunology of vaccines e a brief history
The science of immunology began in the 19th century. Louis
Pasteur and Robert Koch established that microorganisms were
the actual cause of infectious diseases, which greatly advanced
our understanding of the speciﬁc basis of immunity. Pasteur
then disproved the spontaneous generation theory of microbes
and Koch developed his four postulates to establish the
relationship between the individual agent and the cause of
a disease. The discovery of antibodies in 1890 and the passive
immunotherapy of diphtheria with anti-diphtheria toxin antibodies
derived from horses resulted in the ﬁrst Nobel Prize in Medicine
being awarded to Emil von Behring. In parallel, a greater
understanding of the way in which hosts and pathogens interact
was unravelling some of the mysteries surrounding infection and
disease. Host cells that ingested and destroyed invading
microbes were identiﬁed by Élie Metchnikoff and named
phagocytes (literally ‘eating cells’, from the Greek). Metchnikoff
and Paul Ehrlich shared the Nobel Prize in Medicine in 1908 for
their research in immunology.
The 20th century sawmajor advances in immunology and the related
ﬁeld of vaccinology, and recent studies continue to provide profound
insights into immunological mechanisms. Figure 2.1 summarises
some of the important immunological milestones that are of particular
relevance to the understanding of vaccinology and indicates several
key parallel events in vaccine development.Our increased knowledge
of the integrated immune cellular and molecular processes has
facilitated, often with hindsight, an understanding of the principles
underpinning effective vaccination. Vaccine design is now
approached from a more rational, less pathogen-based perspective
and, increasingly, immunology is guiding vaccine researchers
towards new horizons with the potential to improve on nature. As
such, the basic concepts of immunology are an essential component
of the foundations of modern vaccinology.
To understand the immunology of vaccines, it is important ﬁrst to
examine the key players of the immune system (Figure 2.2) and to
Figure 2.1 Immunological milestones of particular relevance to vaccinology. Progress in vaccine design and technology is underpinned
by discoveries in immunology. This is shown by the increasing number of vaccines developed as knowledge of immunity has increased.
HPV, human papillomavirus; Hib, Haemophilus inﬂuenzae type b; OPV, oral polio vaccine; IPV, inactivated polio vaccine; Th, T helper
cell; APC, antigen-presenting cell; PRR, pattern recognition receptor; PAMP, pathogen-associated molecular pattern; IL, interleukin;
TCR, T-cell receptor.
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following section we will discuss the innate and adaptive phases of
the immune response and how these are bridged by the actions of
specialised antigen-presenting cells (APCs) e a key step in the
successful response to vaccination.
Figure 2.2 Key players of the immune system. The innate
and adaptive immune systems are populated by many
different cells that vary in their roles and responsibilities.
CD, cluster of differentiation.
Although we are continuously exposed to
external antigens, foreign substances
and microorganisms, under normal
circumstances food and airborne
antigens do not provoke the immune
system. In addition, some normal
commensal ﬂoras have also co-evolved
with their human hosts to suppress or
avoid triggering defence mechanisms. It
is now known that this is partly because
immune responses are usually only
triggered in the context of threat
or damage to the host; however, both
self and non-self-antigens have the
potential to trigger immune responses
under conditions of acute or
chronic inﬂammation.
28 UNDERSTANDING MODERN VACCINESThe immune system
Physical and chemical barriers comprise the body’s ﬁrst line of
defence e including the skin, ciliated epithelia, mucous membranes,
stomach acids and destructive enzymes in secretions. The immune
system in vertebrates is a network of cells, tissues and organs that
function in a coordinated fashion to defend the body against factors
that could penetrate its physical and chemical barriers. Some of the
key organs of the immune system are illustrated in Figure 2.3, and
include the primary lymphoid organs (bone marrow and thymus)
where lymphocytes are generated, and the secondary lymphoid
organs (peripheral lymph nodes, spleen, tonsils, Peyer’s patches)
where immune responses are initiated and regulated.INNATE AND ADAPTIVE IMMUNITY
All organisms have some form of innate protection against the
outside world, which may be as simple as a cell wall or waxy
Figure 2.3 Organs and tissues of the immune system. The innate immune system is formed from a combination of physical barriers (skin,
mucus), chemical defences (acids, antimicrobial peptides) and specialised cells capable of responding to pathogens without needing to
recognise speciﬁc antigens (A). The adaptive immune system consists of a network of primary and secondary organs, where immune cells are
either produced or reside until they become activated (B).
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30 UNDERSTANDING MODERN VACCINEScoating. As higher organisms evolved, their innate defences
became more sophisticated and the jawed vertebrates
developed a highly specialised system of immunity e acquired
(or adaptive) immunity e which may have evolved as
a consequence of co-evolution with specialised parasites,
increased metabolic rates due to dietary changes, and genomic
instability. Jawed vertebrates thus have two interlinked systems
which act sequentially to establish protective immunity e the
innate immune system and the adaptive immune system. The
innate immune system acts as a ﬁrst line of defence which
comprises both cellular and non-cellular effectors. This system
provides early containment and defence during the lag time
before adaptive immune effectors are available. Innate immunity
comprises both soluble (eg complement, lysozyme) and cellular
effectors (eg natural killer [NK] cells, macrophages and dendritic
cells [DCs]). The innate and adaptive immune systems are
principally bridged by the action of specialised APCs, which
translate and transfer information from the body tissues and
innate immune system to the adaptive immune system, allowing
a systemic response to a localised threat. The innate immune
system therefore drives and shapes the development of adaptive
immune responses via chemical and molecular signals delivered
by APCs to induce the most appropriate type of adaptive
response. The adaptive immune system forms the second,
antigen-speciﬁc line of defence, which is activated and
expanded in response to these signals.The innate immune system
CELLS OF THE INNATE IMMUNE SYSTEM
Cells of the innate immune system are produced in the bone
marrow and then migrate to different anatomical locations. The
innate immune cell repertoire includes tissue-resident cells such as
macrophages and immature DCs, and cells which circulate via
blood and the lymphatic system, such as monocytes, neutrophils,
eosinophils, NK cells and innate T cells. Non-immune system cells
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and mucus-producing cells, ﬁbroblasts and endothelial cells, can
also exhibit innate defensive behaviours.DETECTION OF PATHOGENS
Invading pathogens are detected by the innate immune system
through molecular-sensing surveillance mechanisms. These
mechanisms include detection of pathogens via pattern
recognition receptors (PRRs), expressed by cells of the innate
immune system, which can be secreted, or expressed on the
cell surface, or are present in intracellular compartments (eg
DNA/RNA sensors). Examples of PRRs are the transmembrane
Toll-like receptors (TLRs) and Table 2.1 lists the qualities of
several TLRs. The model system in Figure 2.4 illustrates the
location of the main human PRRs, and highlights the signalling
pathways of several mammalian TLRs.
The key feature of cells of the innate immune system is their ability to
directly recognise different classes of pathogens e eg viruses and
bacteria e by PRRs. These receptors are able to bind to molecules
(such as bacterial membrane components) that are shared
by several pathogens (eg all Gram-negative bacteria express
lipopolysaccharide [LPS]), enabling the innate immune system to
sense the occurrence of an infectious event. Recently, DCs and
macrophages have been shown to react to signals released by
damaged cells, indicating that the innate immune system can
react to both the presence of infectious microbes (via
pathogen-associated molecular patterns [PAMPs]) and to the
consequences of an infectious event.
Epithelial cells, ﬁbroblasts and vascular endothelial cells are also
able to recognise PAMPs, and signal to innate immune cells when
infected, stressed or damaged. This is mediated by stress signals
(such as heat-shock proteins) and active small-molecule peptides
(such as defensins, lysozymes and cathelicidins) which have
direct antimicrobial properties and also act to alert immune cells.
Specialised chemical messengers, including cytokines and















TLR5 Bacterial ﬂagellin Cell surface
TLR6 Mycoplasma Cell surface
TLR7 Bacteria Cell compartment
TLR8 Single-stranded DNA Cell compartment
TLR9 Pathogen CpG DNA Cell compartment
This table provides examples only and is not intended to be an exhaustive list. CpG, adjacent cytosine (C) and guanine (G) residues in a
linear sequence connected by a phosphodiester bond (see Chapter 4 e Vaccine adjuvants, Figure 4.9).
The local reactogenicity observed
followingvaccinationprobablyreﬂects the
inductionof local inﬂammatoryresponses,
which are important in the initiation of a
successful immune response.
32 UNDERSTANDING MODERN VACCINESchemokines, are secreted by stressed/damaged cells and innate
immune cells to attract other resident and circulating innate cells to
the site of infection. Cells dying due to infection also release other
small molecules, such as urea, which alert DCs.
Appendices, Supplementary Table 1 shows some examples of
the innate biological consequences of signalling through PRRs.
The downstream adaptive responses triggered by these signals
are determined by the intracellular signalling pathway into which
the signal feeds. Further ﬁne-tuning of these responses to speciﬁc
outcomes is believed to be achieved via the recruitment of
speciﬁc intracellular adaptor molecules, which modify and
manipulate the signal sent to the nucleus of the innate cell to tailor
the proﬁle of gene expression. Redundancy exists in pathogen
detection systems, as multiple receptors may recognise the same
pathogenic structure and, conversely, a single receptor may be
Figure 2.4 Cell-surface and intracellular PRRs. TLRs are a class of pathogen receptors that are known to recognise many PAMPs including
surface antigens and/or a pathogen’s genetic material (A). For example, TLR4 is positioned at the cell surface and recognises bacterial and
viral antigens, whereas TLR9 is located intracellularly and recognises bacterial and viral DNA. Transmission of the signal is mediated by
intracellular adaptor molecules (B). Activation of these messengers triggers the movement of transcription factors to the nucleus, where
proinﬂammatory gene expression is induced or enhanced. There are many opportunities in the signalling pathways for the cell to recognise
a PAMP and become responsive, maximising the chances of pathogen detection.
PAMP, pathogen-associated molecular pattern; LPS, lipopolysaccharide; TLR, Toll-like receptor; DS, double stranded; SS, single stranded;
CpG, adjacent cytosine (C) and guanine (G) residues in a linear sequence connected by a phosphodiester bond.
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The inﬂammatory response
The local inﬂammatory response aims to
rapidly recruit innate effector cells to an
infected or damaged body site. The local,
elevated secretion of cytokines and
chemokines causes an increase in blood
vessel permeability and the release of
plasma, producing the swelling, redness,
pain and heat that are typical symptoms
of inﬂammation. Inﬂammation is also a
protective response that helps to initiate
the healing process. Soluble factors
produced during an innate response can
damage healthy cells; inﬂammation
therefore needs to be a closely
regulated process.
34 UNDERSTANDING MODERN VACCINEScapable of delivering more than one signal to the host cell.
Overall, the integration of these signals by APCs leads to their
activation. This enables them to act as messengers to precisely
deﬁne the nature of the perceived danger and convey this
information to the secondary lymphoid organs, where they
interact with, and speciﬁcally activate, the relevant adaptive
immune response.EFFECTORS OF THE INNATE RESPONSE
Under some circumstances, pathogen clearance may be achieved
by innate immune effectors without activation of an adaptive
immune response. Activated innate cells act as phagocytes,
engulﬁng and destroying the pathogen within intracellular vesicles
containing digestive enzymes. To be efﬁcient, this response
requires both the recruitment and activation of phagocytes at the
site of infection, a process often referred to as the inﬂammatory
response. Cells residing in proximity to the infection site are
activated upon recognition of PAMPs, and secrete a large array
of soluble mediators, including chemokines and cytokines
(Figure 2.5). Chemokines behave as chemoattractants (Appendices,
Supplementary Table 2), favouring the recruitment of innate immune
cells to the site of infection, while cytokines (including tumour necrosis
factor and interferons) (Appendices, Supplementary Table 5) act by
increasing the phagocytic activity of cells. Innate immune cells also
produce a series of soluble chemical factors (such as peptides) that
are able to directly target the invading microbes.
Additionally, antigens are taken up by innate cells, with immature
DCs the most specialised among them. The antigen is subsequently
processed and the DC differentiates into an APC. Antigen-carrying
APCs then migrate to the draining lymph node and provide the link
between the innate and adaptive immune responses.Complement
The complement system consists of approximately 25 proteins that
work together to ‘complement’ the action of the adaptive immune
Figure 2.5 Innate effector mechanisms. The innate immune system responds to challenge by secreting factors that directly kill or inhibit the
invader; or that attract more cells capable of removing the threat and, if necessary, alerting the adaptive immune system. Tissue-resident
cells, such as macrophages, secrete antimicrobial factors in response to proinﬂammatory stimuli. Circulating cells are recruited to the site by
chemotactic stimuli, released by damaged or infected epithelial and endothelial cells and other innate immune cells. If innate effectors
contain and remove the invader, infection can be resolved without the intervention of the adaptive immune response. Additionally, antigens
are taken up by immature DCs. The antigens are processed intracellularly and the cell transforms into an APC followed by migration to the
draining lymph node.
DC, dendritic cell; APC, antigen-presenting cell.
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The diversity of adaptive
immune receptors
In contrast to innate cells which express
a few dozen pathogen-speciﬁc receptors,
lymphocytes can express an enormous
diversity of antigen-speciﬁc receptors
(around several thousand billion),
a number that far exceeds the total
number of genes present in our genome
(around 25,000). Antigen receptors are in
fact encoded by a set of ‘mini-genes’ that
undergo complex recombination events,
allowing the generation of diverse
proteins from a limited number of building
blocks. Additional individual changes and
random insertions in the genes further
increase the diversity of the receptors.
The vast T- and B-cell repertoires that
humans possess provide a massive
potential for antigen-speciﬁc responses.
This repertoire is maintained with single
or very fewcells expressing receptors that
will recognise any given antigen, until
individual clonesare selectively expanded
in response to a speciﬁc challenge.
Notwithstanding these abilities of the
adaptive immune system, rare individuals
may have a genetic makeup that does not
enable them to react to one or other
antigen present on a pathogen.
36 UNDERSTANDING MODERN VACCINESresponse in destroying bacteria. Complement proteins circulate in
the blood in an inactive form. Once activated, complement
components serve several effector roles including the recruitment
of phagocytes, the opsonisation of pathogens to promote
phagocytosis, the removal of antibodyeantigen complexes and the
lysis of antibody-coated cells.
The adaptive immune system
One critical function of the innate immune system is to alert
the adaptive immune response, whereby lymphocytes with
antigen-speciﬁc receptors are activated and proliferate to ﬁght the
pathogenic threat. Their antigen receptors evolved in response to
the selection pressure of different pathogens and therefore have
very diverse characteristics.
Lymphocytes can be found circulating in the blood/lymph and
residing within secondary lymphoid organs, such as the lymph
nodes and spleen. There are two main subsets of lymphocytes
involved in adaptive immune responses, whose nomenclature
reﬂects the site of their development e B cells develop in the bone
marrow and T cells develop in the thymus.
The adaptive immune system essentially functions via the production
of three key types of effector: antibodies (produced from B cells),
cytokines and cytolytic molecules (produced by Tcells) (Figure 2.6).THE FACILITATORS AND EFFECTORS OF THE ADAPTIVE
IMMUNE RESPONSE
Facilitators: the role of the APC
The ﬁrst cells to interact with an incoming pathogen are often the
phagocytes of the innate immune system, which can engulf and
degrade pathogens. However, it is now clearly recognised that
professional APCs, typiﬁed by DCs, can ingest pathogen-derived
proteins, partially digest, process and transport the peptide
products to the cell surface, rather than targeting them for
complete destruction.
Figure 2.6 Adaptive immune effectors. Adaptive immune effectors are recruited to the site of challenge and also circulate systemically to deal with
any disseminated pathogens/antigens. Adaptive effectors can act by interacting directly with the pathogen, or by modulating the action of innate
immune effectors. CD4þ cells often represent the ﬁrst lymphocyte subset activated during an adaptive immune response and are able to affect the
behaviour of other immune cells (thereby acting as ‘helpers’). Soluble antibodies reaching the site of infection perform effector functions such as
enhancing phagocytosis (greater detail on antibody effector functions is provided in Figure 2.7). CD4þ T cells expressing a Th1-type phenotype
activate macrophages locally via secretion of proinﬂammatory cytokines, increasing their phagocytic and antimicrobial activity. CD8þ T cells
recruited to the site of infection/inﬂammation express surface molecules that are directly cytotoxic to infected target cells via apoptosis but can
also exert antiviral activity on these cells via cytokines.




MHC molecules display antigenic
peptides to Tcells. MHC class I molecules
receive endogenous proteins, including
those derived from intracellular
pathogens, and are expressed by virtually
all nucleated cells of the body.MHCclass I
peptides are recognised by the T-cell
receptor (TCR) expressed by CD8D Tcells.
MHC class II molecules are usually
expressed by a restricted set of cells such
as macrophages, DCs and B cells. They
present peptides derived from exogenous
antigens, taken up via mechanisms such
as endocytosis and phagocytosis.
Antigenic peptides presented by MHC
class II molecules are bound by TCRs
expressed by CD4D T cells.
38 UNDERSTANDING MODERN VACCINESThese pathogen-derived peptide antigens are bound by
a specialised set of receptors known as human leukocyte antigens
(HLA) that act as ‘antigen-presenting’ molecules. These molecules
are encoded by a gene family called the major histocompatibility
complex (MHC). DCs displaying pathogen-derived antigen on the
cell surface are also endowed with migratory properties that allow
them to leave the infected site and migrate towards the nearest
lymph node. DCs therefore represent an important cellular
messenger, able to transport molecular pathogen fragments to
secondary lymphoid organs. Antigen fragments displayed by DCs
are destined to activate pathogen-speciﬁc T cells residing in the
lymph nodes.
Facilitators: T-cell activation
T cells represent a subset of lymphocytes that differentiate within
the thymus, a small bi-lobular organ situated in the anterior
mediastinum. Each T cell expresses a unique antigen-speciﬁc
receptor (the TCR) with a unique recognition capacity.
T cells do not directly recognise whole pathogens, but are only
speciﬁcally activated by DCs transformed into APCs which present
molecular fragments (mostly peptides derived from limited
digestion of protein antigens) in association with MHC molecules
at the cell surface. Naïve lymphocytes are therefore ‘blind’ to live
microorganisms and need the help of APCs to adequately react to
an invading pathogen.
Facilitators: CD4D T cells
An individual naïve Tcell can only be activated by a protein antigen
for which it has a speciﬁc receptor, and which has been processed
and presented by an APC. Cells activated by antigen-bearing DCs
express the cluster of differentiation (CD)4 cell-surface protein, and
are thus referred to as CD4þ Tcells. These cells often represent the
ﬁrst lymphocyte subset activated during an adaptive immune
response, and play both modulatory and effector roles during an
immune response. CD4þ cells act primarily by secreting soluble
factors (cytokines) that are able to exert direct antimicrobial
Identiﬁed around 2005, Tfh cells were
thought to be part of the Th2 subset
based on the proﬁle of cytokines they
produced, but have subsequently been
identiﬁed as a distinct subset of T cells
that fulﬁl some of the roles originally
attributed to Th2 cells.
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cases, CD4þ cells help other immune cells perform their task and
are, therefore, referred to as helper Tcells (Th). Based on the types
of cytokines they secrete and differing abilities to help other subsets
of immune cells, several sub-populations of Th cells have been
identiﬁed (Appendices, Supplementary Table 3).
One subset of Th cells, the Th1 cells, appear to secrete mainly
interferon-gamma (IFNg), a cytokine known to limit pathogen survival
and spreading. It is also known to promote the differentiation of
cytolytic cells that are able to destroy cells infected with intracellular
pathogens (see CD8þ T cells). Th1 cells are, therefore, considered
important for inducing immune responses involved in the clearance
of pathogens.
Another subset of T helper cells, the Th2 cells, produce cytokines
(interleukins [IL] IL-4, IL-5, IL-13) that appear particularly apt at
activating innate cells (eosinophils, mast cells) which are often
involved in the immune response to large extracellular parasites.
Another subset, termed follicular T helper cells (Tfh) based on their
tissue localisation in follicular structures, have been deﬁned by
secretion of IL-21, a cytokine thought to favour the secretion of
antibodies by antigen-speciﬁc B cells.
Activation of CD4þ cells represents a key step in setting in
motion an adaptive immune response. Through their ability
to secrete cytokines, these helper cells will augment the capacity
of other immune cells to perform their tasks. The adaptive
immune response is frequently characterised by two effector
cell populations, the CD8-expressing cytolytic T cells and the
antibody-secreting B cells.
Adaptive effectors: CD8D T cells
CD8þ T cells exploit the TCR/MHC interaction around
pathogen-derived peptides to detect and ﬁght intracellular
pathogens. To achieve this, CD8þ Tcells rely on the fact that virtually
all nucleated cells (with a few notable exceptions) present fragments
of intracellular proteins at their surface as part of the body’s normal
40 UNDERSTANDING MODERN VACCINESsurveillance processes. In contrast to classically deﬁned APCs, which
display antigenic fragments in association with MHC class II
molecules, non-immune cells use a closely related set ofmolecules to
display peptides derived from the cytoplasm e the MHC class I
molecules. This complex mechanism of antigen presentation allows
CD8þ Tcells to scan proteins fromwithin the cell, while preserving the
integrity of the cell membrane.
The salient feature of CD8þ Tcells is their ability to secrete cytotoxic
factors in addition to cytokines. These factors enable CD8þ T cells
to kill cells displaying pathogen-derived peptides presented by
MHC class I molecules, for example a virus-infected cell. By killing
cells expressing high levels of virus-derived peptides at their
surface, CD8þ cells are able to eliminate infected cells before the
completion of a viral replication cycle, thus limiting viral spread
within an infected individual. In addition, CD8þ Tcells can inhibit viral
replication without destroying the target cells by producing
cytokines that are able to interfere with pathogen replication.
CD8þ cytolytic cells can also eliminate cells displaying abnormal
host peptides, such as those presented by tumour cells, and
therefore play an important role in the immune control of aberrant
cell growth. Although CD8þ T cells can directly react to cells
expressing the appropriate antigen/MHC class I complexes, their
optimal activation programme (proliferation and acquisition of full
cytolytic potential) is best achieved in the presence of cytokines
produced by type 1 CD4þ T helper cells.B cells and antibodies
Antibodies represent a highly diverse set of soluble proteins
secreted by the subset of lymphocytes referred to as B cells. B cells
develop in the bone marrow before undergoing a process of
differentiation and maturation in the spleen. As with T lymphocytes,
each B lymphocyte expresses a unique antigen receptor (B-cell
receptor [BCR]) enabling the cells to react to a speciﬁc antigen. In
marked contrast to TCRs, BCRs can directly bind to molecules
expressed by pathogens, with no need for previous internalisation
Antibodies play multiple roles in the
control and elimination of pathogens,
and in the response to vaccination.
Binding of targets by antibodies is often
sufﬁcient to initiate processes that
render the pathogen harmless.
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antigen encounter, B cells expressing the cognate BCR are induced
to proliferate and differentiate into plasma cells, which can secrete
large amounts of a soluble form of the BCR that we know as an
antibody. This soluble protein is thus released in the blood and other
body ﬂuids (referred to as the ‘humors’) enabling them to ﬁght
infection at distant sites.
Antibodies can be viewed as bifunctional molecules, able to both
recognise and eliminate a given antigen or pathogen. Antibody
molecules consist of a ‘constant’ fragment, a structural feature
common to all antibodies of a given isotype, and a ‘variable’
region, which includes the portion that gives the antigen
speciﬁcity (or antigen-binding characteristics) of the antibody.
The variable region of the antibody can exist in a huge number
of molecular conﬁgurations, and an individual’s BCR repertoire is
generated to maximise capability to produce antibodies that are
useful against diverse potential pathogenic threats. The constant
part of the molecule exists in ﬁve different forms (isotypes)
(immunoglobulin [Ig] A, IgD, IgE, IgG and IgM, see Appendices,
Supplementary Table 4) that determine the ability of an antibody
class to localise to particular body sites and target speciﬁc types
of infection, and to recruit the optimal local effector cells (see
Figure 2.7).
B cells can differentiate into antibody-secreting cells upon
encounter with a given antigen or pathogen. In most cases,
direct activation of B cells by an antigen is observed in response
to repetitive antigenic structures, such as carbohydrates found
in bacterial walls. These T cell-independent responses are
characterised by the secretion of low-afﬁnity antibodies of the
IgM type. This type of response is often stereotyped in nature,
lacking the typical memory response upon re-exposure to the
same antigen (see section titled Immunological memory).
In most cases, optimal B-cell activation and differentiation into
antibody-secreting plasma cells is only observed when both B
and T cells are simultaneously activated by the same pathogen.
Figure 2.7 Effector functions of antibodies. Antibodies play multiple roles in the control and elimination of pathogens and in the response to
vaccination. Antibodies can bind directly to the surface of pathogens (1) or soluble mediators (2) preventing infection of host cells and
neutralising pathogen-derived toxins. Antibodies can recruit effector molecules such as complement (3) or activate effector cells via their Fc
portion (4, 5). Binding of the Fc region of an antibody to a speciﬁc Fc receptor expressed by innate cells can facilitate pathogen internalisation
and destruction by phagocytes (by a process referred to as ‘opsonisation’) (4). Similarly, ligation of Fc receptors on granulocytes promotes
their degranulation and triggers potent antimicrobial responses including the removal of antibodyeantigen complexes and the lysis of
antibody-coated cells (5).
Fab, fragment antigen binding; Fc, fragment, crystallisable.
42 UNDERSTANDING MODERN VACCINESIn these instances, CD4þ T cells differentiate into Tfh cells that
are able to provide a helper signal to B cells. T cell-dependent
B cell responses are characterised by the secretion of
high-afﬁnity antibodies and a large spectrum of isotypes (in
particular IgG), and are typically associated with immunity
resulting from natural exposure.
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Cytokines are small proteins secreted by activated innate and
adaptive immune cells (such as DCs, macrophages and T cells),
which direct the activity of other cells to coordinate an appropriate
immune response. Cytokines are a diverse family of molecules
which include interleukins, interferons and growth factor responses
(Appendices, Supplementary Table 5). Cytokines may act in an
autocrine, paracrine or endocrine fashion, by binding cell-surface
receptors and stimulating signalling pathways, ultimately affecting
the gene expression of the target cell. Cytokines are referred to as
either proinﬂammatory or anti-inﬂammatory, depending on their role
during the establishment of immune responses. These two types
then act together to control and regulate different aspects of the
immune response.Agenetic deﬁciencyof Treg cells results in
severe autoimmune syndrome;
conversely, infection may be established
where responses are inappropriately
suppressed by selective activation of Treg
cells, for example by the stomach
pathogen Helicobacter pylori. Over-
suppression of immune responses by
regulatory mechanisms may also result
in an inadequate response to vaccination
in some individuals.REGULATORY T CELLS
Immune responses are prevented, down-regulated or terminated by
multiple mechanisms. These mechanisms include clonal deletion,
the activity of suppressor monocytes and anti-inﬂammatory
cytokines, induction of apoptosis, induction of unresponsiveness
by resting APCs, expression of inhibitory cell-surface co-receptors
and the activity of regulatory CD4þ T cells.
Regulatory Tcells (Treg cells) belong to the CD4
þ T-cell subset. Their
role is to inhibit immune or inﬂammatory responses by blocking the
activity of effector T cells, helper T cells and APCs. They are key to
the down-regulation of immune responses at the appropriate point
following a protective response, the immunological tolerance
process (avoiding immune response towards self-antigens and
non-threatening antigens, eg from food and commensal ﬂoras),
and prevention of uncontrolled or chronic inﬂammatory responses.
Antibodies produced during the immune response may also
down-regulate subsequent immune responses, for example by
elimination or masking of antigen, hence limiting the activation of
additional T cells. Antibodyeantigen complexes may also bind to
inhibitory receptors, initiating suppressive responses.
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Upon differentiation, naïve Tand B cells, each expressing a unique
TCR and BCR, migrate to the blood and peripheral lymphoid
organs. Due to the large number of possible immune receptors,
lymphocytes expressing a given antigen speciﬁcity will be too
infrequent to mount an effective immune response on their own.
Thus, upon antigen encounter, T and B lymphocytes must undergo
rapid proliferation, leading to the accumulation of an increased
number of cells expressing receptors for the incoming antigen.
Some of these cells will differentiate into effector cells (such as
cytokine-producing T cells or antibody-secreting plasma cells),
while others will become ‘memory cells’, able to survive for a long
period of time within the host.
Exposure to an antigen (pathogen or vaccine) therefore leads to
a long-term (and sometimes permanent) modiﬁcation of the
cellular repertoire, such that the relative frequency of T and B cells
speciﬁc for an individual antigen is increased in antigen-exposed
individuals compared with naïve individuals (Figure 2.8). In
addition to their increased frequency, memory T and B
lymphocytes also display novel functional properties, enabling
them to develop secondary (recall) responses on re-encounter
with their speciﬁc antigen, or a closely related antigen. The
adaptive response on secondary exposure leads to a rapid
expansion and differentiation of memory T and B cells into
effector cells, and the production of high levels of antibodies.
A higher proportion of IgG and other isotypes of antibodies
compared with the level of IgM characterises memory
antibody responses.
By deﬁnition, all effective vaccines lead to the development of
immune memory, by mimicking the threat of an infection and
providing antigens derived from the speciﬁc pathogen. The
ability to generate immune memory is the key attribute of the
adaptive immune system, which is crucial for the long-term
protection of individuals and populations. Generating immune
memory depends on a high degree of interaction among many
Figure 2.8 The kinetics of primary and recall (memory) immune responses. On ﬁrst exposure to a pathogen or antigen (referred to as ‘priming’ in
vaccination), the innate immune system must detect, process and translate the threat into a form that can be understood by the adaptive immune
system. This occurs via the bridging actions of APCs and takes days/weeks. Following resolution of the challenge, a specialised ‘memory’ cell
population remains. The cells within this population are maintained for a long time (months/years) and may remain within the host for the rest
of their host’s life. On subsequent exposure to the same antigen (referred to as ‘boosting’ in vaccination), the innate immune response is
triggered as before but now the memory cell populations are able to mount a greater and more rapid response as they do not need to
undergo the same activation process as naïve cells.
APC, antigen-presenting cell; IgM, immunoglobulin M; IgG, immunoglobulin G.
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46 UNDERSTANDING MODERN VACCINESdifferent cell types, which maintains higher numbers of T and B
cells that were selected as the most useful in the primary
immune response. However, while the relative contribution of
clonal memory cells to protection can be inferred from the
molecules they express and their functional behaviour, the
presence of memory cells per se is not indicative of absolute
protection against disease.
There are several theories as to how new effector cells are
generated from memory cells when needed, and it is likely that all
of these mechanisms play a role in immunological protection.
One possibility is that short-lived effector cells are produced
continuously by memory cell division, replacing the older cells of
the same speciﬁcity e this process would be driven by the
persistence of antigen. Long-lived effector cells may also be
generated from memory cells in a process driven by cytokines
and engagement of PRRs in response to a new encounter with
the pathogen. A third possibility is that effector cells remain for
long periods in specialised survival niches e there is some
evidence that this is an important mechanism in B-cell memory,
since depletion of memory B cells does not signiﬁcantly impact
the level of circulating antibodies, probably due to the presence of
long-lived plasma cells.Summary of differences between the
innate and adaptive immune systems
As we have seen, the innate and adaptive immune systems occupy
distinct evolutionary and functional niches. The innate immune
system, along with physical and chemical barriers, provides a ﬁrst
line of defence against invasion or damage. A system of cellular and
soluble mediators then transmits the nature of the threat to the
adaptive immune system, which selectively expands the appropriate
repertoire in order to deal with the threat. The key differences
between these two systems are summarised in Table 2.2. In the
next section, the mechanisms linking innate and adaptive immunity
will be discussed.
TABLE 2.2. KEY DIFFERENCES BETWEEN INNATE AND ADAPTIVE IMMUNITY
Innate immunity Adaptive immunity
First line of defence against pathogens Second line of defence against pathogens
Acts rapidly (hours/days), vital to triggering of adaptive responses Relatively slow to develop (days/weeks)
Triggered by threat/damage Triggered by exposure to speciﬁc antigen
Activated by microbial general patterns and damage Very focused, targets a speciﬁc pathogen
Acts through pathogen class-speciﬁc mechanisms of
neutralisation/control
Acts through antigen-speciﬁc and non-speciﬁc effectors
No recall response on subsequent exposure to same threat Rapid recall response on subsequent exposure to same antigen
(immunological memory)
Initiates processes of tissue repair
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are bridged by the actions of APCs
As previously discussed, the innate immune system provides an
essential link between the ﬁrst encounter with a pathogen at the site
of infection and the eventual establishment of immune memory.
Innate cells (such as macrophages and DCs) are strategically
located at body sites with a high risk of infection (such as epithelia
and mucosal surfaces). These types of cells act as both a ﬁrst line of
defence against danger and as key messengers that are able to
alert the adaptive immune system. Since naïve Tand B cells are not
pre-positioned in most organs and tissues of the body, they rely on
the innate immune system to sense an infectious event.
Among tissue-resident cells, the most efﬁcient APCs are DCs.
Immature DCs which have captured antigen become activated
and mature into functional APCs, while migrating to the regional
draining lymph node or submucosal lymphoid tissue. Mature DCs
express high levels of antigen/MHC complexes at the cell surface
and undergo morphological changes, which render them highly
specialised, to activate naïve Tcells. When they arrive in the lymph
node, DCs present processed antigen and express co-stimulatory
signals. The signals provided by DCs promote T-cell differentiation
and proliferation, initiating the adaptive T cell-mediated immune
48 UNDERSTANDING MODERN VACCINESresponse. APC activation is therefore a necessary prerequisite for
an efﬁcient adaptive immune response.
DCs not only provide antigen and co-stimulation to naïve T cells,
but also contribute to the initial commitment of naïve T helper cells
into Th1, Th2 or other subsets. This directs the efﬁcient induction of
T helper cells with appropriate cytokine proﬁles early during
infections, without the need for direct contact between
antigen-speciﬁc T cells and pathogens.
Undigested pathogen-derived antigens are also drained by the
lymph and transported to the B cell-rich area of the lymph node,
where they are exposed to BCR-expressing cells. An adaptive
immune response is therefore initiated in a draining lymph node by
the concerted action of innate immune cells and free antigens.
These activate Tand B lymphocytes, respectively, to proliferate and
differentiate into effector and memory cells.
The type of communication employed by the immune system
represents a unique approach to multi-system signalling and
communication over distances. As well as employing the
soluble mediators e proinﬂammatory messengers, chemokines
and soluble danger signals e the immune system uses
migratory APCs to physically transport messages from the
periphery to the induction sites of adaptive immune response,
eg in lymph nodes.
Notably, by selectively migrating in response to infectious/
cell-damaging events, DCs act as ﬁlters for the adaptive immune
response, helping T and B cells to ignore innocuous foreign
antigens. Thus, the innate immune response plays an important role
in selecting antigens that represent a real threat to the organism that
requires an adequate adaptive response.The immune response e summary
The response to pathogens in humans takes place over a large
anatomical distance and in distinct phases, which are summarised
in Figure 2.9.
Figure 2.9 An overview of the human immune response. The innate immune response is initiated (1). Innate immune cells begin to mature and
differentiate, while migrating to the lymph nodes (2). APCs induce the adaptive immune response including activation of T cells into effector cells
and differentiation of T cells into memory cells (3e5). Naïve B cells differentiate into antibody-secreting plasma cells and memory B cells following
activation by helper CD4þ T cells (6) and activated CD4þ T cells activate tissue-resident macrophages (7). Antibodies can enhance the effector
functions of innate cells (8) and also neutralise pathogens directly (9). Cytotoxic T cells can directly kill infected tissue/cells via molecular and
chemical signalling (10) and also induce infected cells/phagocytes to kill intracellular pathogens, or inhibit pathogen replication (11). Not all
T cell subsets are represented in this illustration.
APC, antigen-presenting cell; CD, cluster of differentiation.
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when a foreign entity triggers a defensive response, which is
mediated by chemical signals. These signals attract responding
innate immune cells (monocytes, DCs etc) which travel to the site
and engulf fragments of the pathogen. The monocytes and DCs
then leave the site via lymphatic vessels and begin to mature and
differentiate, while travelling to the local draining lymph nodes.
Differentiation gives rise to APCs that interact with naïve Tcells at the
lymph nodes and bear receptors for the antigenic peptides
expressed on the surface of the APC. Molecular, antigenic and
cytokine signals combine to direct the differentiation and activation
of CD4þ T cells into distinct effector subtypes. This is the induction
phase of the adaptive immune response.
A sub-population of CD4þ T cells differentiates into memory cells,
which are capable of responding rapidly on repeat exposure to the
same antigen. CD8þ T cells also receive antigenic and cytokine
stimulation from APCs and undergo differentiation either into
memory-type cells or armed effector cytotoxic cells. Activated
helper CD4þ Tcells interact with antigen-bearing naïve B cells and,
via molecular and cytokine signals, direct their activation into
i) antibody-secreting plasma cells, and ii) memory populations that
persist for long periods. Activated CD4þ Tcells also travel to the site
of infection and, via cytokine signals, activate tissue-resident
macrophages to become fully active and to destroy
phagocytosed antigen/pathogens.
Antibodies can enhance the effector functions of innate cells, for
example, by enhancing phagocytosis. Soluble antibodies at the site
of challenge can neutralise pathogens directly by binding to their
surface. Cytotoxic T cells can directly kill infected tissue/cells via
molecular and chemical signalling. These cells can also induce
infected cells/phagocytes to kill intracellular pathogens, or can
inhibit pathogen replication via chemical and molecular signals.
On secondary exposure to the same antigen or pathogen, speciﬁc
adaptive effectors with a memory phenotype can rapidly proliferate
and produce a new wave of adaptive immunity at the site of
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immune events and is the basis of vaccination.
The coordination of all these phases ensures that a call for help from
the periphery is relayed to the regional secondary lymphoid tissues
and that appropriate effectors are directed to the site of infection by
a series of chemical and molecular signals. This cycle of an immune
response forms the basis for the principles of vaccination
(Figure 2.10) and is discussed further in the next section.Figure 2.10 The ﬂow of information following
intramuscular vaccination. An antigen
delivered by a vaccine is taken up by
macrophages and immature APCs (1). APCs
migrate to the lymph node draining the site of
vaccination (2). The adaptive immune response
is now initiated and effectors, such as CD4þ
effector T cells, cytotoxic T cells and soluble
antibodies (3), are produced which travel
throughout the bloodstream and back to the
site of vaccination.
APC, antigen-presenting cell.
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to vaccinology
The modern immunology concepts described in this chapter are
of great importance both for the design of new vaccines and to help
us understand why vaccines do e or do not e work as efﬁciently
as desired.IMMUNOLOGICAL REQUIREMENTS OF A VACCINE
Identiﬁcation and selection of the most appropriate antigen
Vaccines aim to prevent the disease symptoms that are the
consequences of a pathogenic infection. In most cases, this does
not occur by completely preventing infection but by limiting
the consequences of the infection. As discussed earlier, an
understanding of the disease pathogenesis and natural immune
control is, therefore, very useful when selecting appropriate
antigens upon which to base a vaccine.
Vaccines developed from pathogens can vary in the complexity of
the pathogen-derived material they contain. Our understanding of
fundamental immunology, as well as the selection techniques used,
has resulted in new vaccines that are better characterised than ever
before, and has also initiated a more rational approach to vaccine
design. The different approaches to antigen selection are
discussed in depth in Chapter 3 e Vaccine antigens.
Induction of innate immune responses
The immune system is triggered by a combination of events and
stimuli, as described previously. The requirement for more than the
presence of a ‘foreign’ antigen to elicit an immune response must
therefore always be considered in vaccine design, particularly when
using highly puriﬁed or reﬁned antigens (see Chapter 3 e Vaccine
antigens). Highly reﬁned subunit antigen formulations, and some
inactivated whole pathogens, do not contain many of the molecular
features and defensive triggers that are required to alert the innate
immune system. These types of antigen are designed to minimise
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suboptimally immunogenic. Under these circumstances, the
addition of adjuvants (see Chapter 4 e Vaccine adjuvants) can
mimic the missing innate triggers, restoring the balance between
necessary defensive responses and acceptable tolerability.
Induction of CD4D T cell help
The induction of CD4þ Tcells is essentially controlled by the nature
of this initial inﬂammatory response. Therefore, vaccine adjuvants
can play a role in guiding how CD4þ T cells are induced and how
they further differentiate and inﬂuence the quality and quantity of the
adaptive immune response.
Selection and targeting of effector cells
It is important to recognise that the dominant immune response to
a given pathogen or antigen may not necessarily be the optimum
response for inducing protection; indeed through evolution some
pathogens have developed strategies to evade or subvert the
immune response, as is the case with Neisseria gonorrhoeae, where
the dominant antibody response actually facilitates infection by
preventing complement-dependent bactericidal activity. Antibody
titres are often considered to represent adequate indicators of
immune protection but, as discussed above, may not be the actual
mechanism by which optimal protection is achieved. Useful speciﬁc
so-called immune correlates of immunity/protectionmay be unknown
or incompletely characterised. Therefore, modern vaccine design still
looks to clinical trials to provide information about clinical efﬁcacy
and, if possible, the immunological proﬁles of protected individuals.
Immunogenicity is assessed by laboratory measurement of immune
effectors, typically antibodies. Increasingly, however, speciﬁc T-cell
activation is included in the parameters assessed, as adequate T-cell
immunity may be essential for recovery from some infections and
improved assay techniques have allowed these evaluations to
become more standardised and offer more robust data. This can
then open the door to understanding observed clinical efﬁcacy
(or lack of) and to deﬁning at least some of the features of
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immunological effectors, vaccines can then hope to mimic or
improve on nature’s own response to infection.
VACCINE DEVELOPMENT CHALLENGES
Immune correlates of protection e what, when
and where?
Successful natural immune responses can be measured in
protected individuals and assessed in terms of, for example, the
production of speciﬁc types of antibody or a particular pattern of
cytokine expression by T cells e this gives the correlates of
protection, which can then be reproduced using a vaccine.
Correlates of protection can only be determined from a clinical trial
where protection from disease or infection is determined in cohorts
of vaccinated versus unvaccinated individuals.
The majority of vaccines developed so far have been assessed by
their ability to elicit antibody responses. One example where this is
well deﬁned is rubella, where protective antibody titres can be
reliably assessed to determine whether an individual is protected
post-vaccination. However, immune correlates of protection are not
well deﬁned in many diseases, including human immunodeﬁciency
virus (HIV) where the presence of antibodies is not a correlate of
immunity/protection, since infected individuals develop antibodies
without being protected against disease. This is a signiﬁcant barrier
to HIV vaccine research and reﬂects the generation of variants of the
virus which evade serological effectors such as antibodies. There is
evidence that some highly exposed individuals can develop
resistance to HIV infection, suggesting that immunity and, therefore,
a vaccine are possible. However, the complex immunological
proﬁles of these rare individuals make it difﬁcult to deﬁne the
protective effectors and their immunological triggers.
Historically, the generation of antibodies has been the main goal of
vaccination; however, for future vaccines this may be insufﬁcient or
inappropriate. Thus, developments are focused on the generation
of speciﬁc CD4þ (Th1) lymphocyte or CD8þ cytotoxic T cell
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simplex virus (HSV) and tuberculosis vaccines, where selected
T-cell determinants delivered as recombinant proteins or via live viral
vectors aim to target the CD4þ and CD8þ T-cell compartments.
The need to guide the immune response towards protective
mechanisms has been demonstrated in trials of respiratory
syncytial virus (RSV) vaccines, where exposure of vaccinees to
natural RSV infection led to severe pulmonary pathology
characterised by inﬁltration of mononuclear cells and eosinophils,
suggesting a strongly Th2-biased response. This resulted in
hospitalisations and deaths of at least two young children following
a study in the 1960s. Hence, insufﬁcient knowledge of the factors
affecting natural control of an infection or the inability to balance the
integrated immune response induced by a vaccine can affect the
ability to produce a safe, effective vaccine.Hostepathogen interactions in vaccine immunology
Vaccine immunology is greatly affected by the complex interactions
that occur between the host and the pathogen. These interactions
can determine the type of immune response a vaccine needs to
induce to offer protection against an actual challenge. Many
pathogens have complex life cycles and sophisticated strategies
which allow them to be successful in their pathological niche. This
may be as simple as a waxy coating which makes opsonisation
more difﬁcult, or as complex as the ability to modulate host gene
expression and manipulate or change the molecular signals
displayed by infected cells. Examples of the immunological
challenges posed by some pathogens are discussed below.Bacteria
Mycobacterium tuberculosis is a good example of a bacterial
pathogen with several defensive mechanisms. These include an
unusual waxy coating which facilitates survival once the bacterium
is taken up into APCs e this is particularly effective as it allows the
bacterium to escape from degradation within macrophages,
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M. tuberculosis is able to down-regulate the expression of
antibacterial immune effectors, such as nitric oxide, by infected
macrophages. The intestinal Gram-negative pathogen Salmonella
enterica is able to modify its LPS into a form that is less identiﬁable
by TLR4. Impairment of the LPS/TLR4 interaction reduces early
activation of the innate immune response and hence allows
Salmonella to better survive and proliferate within the host’s
intestinal cells.Viruses
Viruses such as cytomegalovirus (CMV) also have highly evolved
host avoidance strategies. This member of the herpesvirus family
has evolved multiple genes for the manipulation of host immunity,
including those whose products prevent the display of viral proteins
in association with MHC class I molecules (hence avoiding
triggering or being targets of speciﬁc CD8þ cytotoxic T cells) by
both diverting viral products out of the degradation pathway and by
suppressing expression of MHC class I molecules. Ordinarily, this
would attract the attention of NK cells, which are activated by
nucleated cells lacking surface expression of MHC class I
molecules. However, CMV possesses genes encoding MHC class I
mimics, which are expressed on the surface of infected cells and
are able to bind to receptors which switch off the cytotoxic activity of
circulating NK cells.Parasites
Parasites present a challenge to vaccine design because the
parasite life cycle comprises distinct phases within a single host,
during which it will reside in different anatomical locations and, most
importantly, express different surface antigens. Thus, parasites
represent an immunological ‘moving target’. In addition, the immune
response to parasites is very complex and may be modulated by the
parasite itself, and hosteparasite interactions are often poorly
deﬁned. There are currently no available vaccines for parasitic
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Phase III clinical trials (see Chapter 6 e Vaccines of the future).IMMUNOLOGICAL IMPEDIMENTS TO EFFECTIVE
VACCINATION e TOLERANCE
Other important considerations in vaccine immunology include the
phenomena of immune tolerance and immunological/antigenic
interference, which can suppress or prevent development of adequate
immune responses following vaccination. Immune tolerance refers to
the induction of immunological non-responsiveness by repeated
exposure to similar antigens, such as polysaccharide antigens; this
effect is dose-dependent and may be limited in time as increasing
the interval between subsequent doses can partially restore
responsiveness. Immunological/antigenic interference occurs
when previous or concomitant exposure to another antigen
prevents the development of adequate responses to the vaccine
antigen, which may be due to previous or concurrent vaccinations.
Another potential cause of reduced vaccine efﬁciency is the
presence of passively induced immunity, eg that transferred from
mother to foetus, where the vaccine antigen is neutralised by
pre-existing maternally-derived antibody without triggering
a host-derived immune response in the infant. These phenomena
can be avoided, however, by taking them into account in
immunisation schedules.Live viral vaccines may cause immuno-
logical interference with each other if
administered at the wrong intervals e for
example, live varicella virus vaccines and
the measles, mumps and rubella vaccine
should be given at the same time or 1
month apart to avoid interference.Modern vaccines e interactions with
the immune system
Vaccines developed within the last decade have beneﬁted from an
increased knowledge of the innate and adaptive immune responses,
and are better characterised in terms of their immunological
mechanism of action than many of their predecessors. It has
become apparent that the most successful vaccines mimic infection
by actively targeting the innate phase of the immune response and
modulating or enhancing the interface bridged by APCs. The
immune response to a vaccine can be substantially improved
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response by providing elements that are normally present in most
pathogens but absent from a highly puriﬁed antigen. The vaccines
which we know most about tend to be those that include an
adjuvant, as the effects of these compounds on the innate immune
system and the downstream adaptive response can be studied
both in isolation and in combination with antigen. There are several
points during the innate response at which adjuvanted vaccines
are known or believed to inﬂuence the subsequent adaptive
immune response, thereby initiating a long-lasting immune
response. This includes modulating or mimicking the interaction
between PAMPs and innate receptors such as TLRs; inﬂuencing
or promoting intracellular signalling pathways; enhancing
antigen uptake by APCs; and up-regulating or modifying
cell-surface crosstalk between APCs and naïve T cells. Some
examples of speciﬁc adjuvanted vaccines that exert direct
effects on the innate immune response are discussed in
Chapter 4 e Vaccine adjuvants.
We are increasingly able to understand the balance between
mechanisms of immune activation and immune regulation. In
parallel, the detailed assessment of the immunological mechanism
of action of vaccines helps us to achieve effective immune
stimulation without inducing a chronic inﬂammatory state. This
information also helps us to reassess the role of vaccines and
natural infections as potential triggers of autoimmune diseases.
Recently, much effort has been devoted to the design of vaccines
that induce CD8þ Tcell responses, as they have a central role in the
host response to viral infections and cancers. However, as yet, it is
not easy to measure the CD8þ T cell response in humans in
a consistent and reliable way; this will remain the focus of research
in the coming years.Conclusion
Advancing knowledge of the immunological mechanisms of action
of existing vaccines provides essential information that is vital to the
VACCINE IMMUNOLOGY 59production of new, well-tolerated, effective vaccines. How
immunological requirements are balanced with the complexities of
the pathogen, the needs of the target vaccinees, the practicalities of
antigen production, and the stability and tolerability of the eventual
vaccine represents a constantly evolving challenge. The factors
affecting the selection and production of different types of antigens
are discussed in Chapter 3 e Vaccine antigens.
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